Propanc Biopharma PPCB 深 滬
已收盤 10-10 16:00:00 美东时间
1.73
-0.150
-7.98%
華盛通- 最 高1.87
- 今 開1.86
- 成交量 19.46万股
- 最 低 1.71
- 昨 收 1.88
- 總市值 2181.84万
- 52周最高 1.87
- 市盈率 靜 --
- 換手率 1.54%
- 52周最低 0.00
- 委 比 41.78%
- 總股本 1261.18万
- 歷史最高 1.87
- 量 比 0.27
- 振 幅 8.51%
- 歷史最低 0.00
- 每 手 1
- 風險率 1.51%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Propanc Biopharma Announces Plans To Establish A $100M Or Greater Digital Asset Treasury Over The Next Year
Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing treatments for recurring and metastatic cancer, announced its fiscal year-end update following the
10-07 20:52
Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy
Propanc Biopharma, Inc. (Nasdaq: PPCB) has completed its fiscal year-end update and filed its annual 10-K report. The company successfully completed an IPO and uplisted to Nasdaq, with significant financial improvements, including total assets rising to $19.6 million and stockholders’ equity reaching $13.9 million. CEO James Nathanielsz highlighted plans to advance therapeutic candidates and build an intellectual property portfolio, as well as cr...
10-07 12:45
Propanc Biopharma Receives Certificate Of Grant From U.S. Patent & Trademark Office For Its Proenzyme Composition Patent
Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a
09-17 20:47
Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office
Propanc Biopharma announced the granting of its fourth US patent for "proenzyme composition," specifically capturing a future clinical dose of its lead asset, PRP, targeting metastatic cancer. The company holds 90 patents in major jurisdictions and plans to advance PRP into a Phase 1B study. PRP, as an EMT modulator, uniquely treats cancer without severe side effects, aiming to address the global metastatic cancer market valued at $111.2 billion.
09-17 12:45
Propanc Biopharma Plans $100M Ethereum Purchase To Diversify Assets And Support Growth
Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced a plan to
09-02 21:08
Propanc Biopharma Provides Shareholder Update
Propanc Biopharma, a biopharmaceutical company, announced it has completed an initial public offering and up-listed on Nasdaq, raising $4 million to advance its lead asset, PRP, into a Phase 1B clinical study in 2026. PRP, a mixture of pancreatic enzymes, targets various cancers and aims to reprogram cancer cells to die naturally. The company also expanded its management team and strengthened its financial position, with plans to pursue strategic...
08-25 11:30
Propanc Biopharma closes public offering, uplists to NASDAQ
Propanc Biopharma (NASDAQ:PPCB) on Tuesday said that it closed an underwritten public offering of 1,000,000 shares of its common stock, at $4.00 per share for gross proceeds of $4M. Shares began tradi...
08-20 01:04
What's Going On With Propanc Shares Monday?
Propanc Biopharma shares are trading higher Monday. The company recently priced a $4 million public offering and began trading on the Nasdaq Capital Market.
08-19 01:57
Why Is Propanc Biopharma Stock (PPCB) Up 150% Today?
Propanc Biopharma stock was up on Monday alongside an uplisting and public offe...
08-18 19:44
Why Dayforce Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket
Shares of Dayforce Inc (NYSE:DAY) rose sharply in pre-market trading. Bloomberg...
08-18 18:51
